FAGR Fagron SA

Disclosure of notification received from FMR LLC

Disclosure of notification received from FMR LLC

Regulated information

Nazareth (Belgium)/Rotterdam (The Netherlands), 20 March 2023 – 6:30 PM CET

Disclosure of notification received from FMR LLC

Fagron received a notification pursuant to the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies from FMR LLC.

Notification of FMR LLC

  • On 16 March 2023, Fagron received a notification that the shareholding of FMR LLC crossed the disclosure threshold of 5% on 15 March 2023 as the result of the disposal of voting securities or voting rights.
  • The notification is made by a ‘parent undertaking or a controlling person’.
  • On 15 March 2023, FMR LLC held a total of 3,639,823 voting rights. 1,738,406 voting rights are held by Fidelity Management & Research Company LLC, 770,002 voting rights are held by Fidelity Institutional Asset Management Trust Company, 605,186 voting rights are held by FMR Investment Management (UK) Limited, and 526,229 voting rights are held by FIAM LLC.
  • Based on the denominator of 72,992, 654 (total number of voting rights), FMR LLC held 4.99% of the total number of voting rights on 15 March 2023.
  • Full chain of controlled undertakings through which the holding is effectively held is as follows: Fidelity Institutional Asset Management Trust Company and FIAM LLC are controlled by FIAM Holdings LLC, FMR Investment Management (UK) Limited is controlled by Fidelity Management & Research Company LLC, FIAM Holdings LLC and Fidelity Management & Research Company LLC are controlled by FMR LLC. FMR LLC is not a controlled entity.
  • The holdings attributed to the entities mentioned above arise from holdings of various undertakings for collective investment that are managed by FIAM LLC, Fidelity Institutional Asset Management Trust Company, Fidelity Management & Research Company LLC, and FMR Investment Management (UK) Limited each of which are entities that are subsidiaries of and controlled by FMR LLC. These entities are the discretionary investment managers and exercise the voting rights at their discretion in the absence of specific instructions.
  • The notification of FMR LLC can be viewed via this .



Further information

Karen Berg

Global Investor Relations Manager

Tel. 99

About Fagron

Fagron is a leading global company active in pharmaceutical compounding, focusing on delivering personalized medicine to hospitals, pharmacies, clinics and patients in more than 30 countries around the world.

Belgian company Fagron NV has its registered office in Nazareth and is listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol ‘FAGR’. Fagron’s operational activities are managed by the Dutch company Fagron BV, which is headquartered in Rotterdam.

In the event of differences between the English translation and the Dutch original of this press release, the latter prevails.

Please open the link below for the press release:



EN
20/03/2023

Underlying

FAGRFagron SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Fagron SA

 PRESS RELEASE
Free
FAGR FAGRON SA

Fagron publishes its Annual Report 2025

Fagron publishes its Annual Report 2025 Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 6 March 2026 7AM CET Fagron publishes its Annual Report 2025 Fagron, the leading global player in pharmaceutical compounding, today publishes its Annual Report 2025, further to its earlier announcement of Fagron's annual financial results for the financial year 2025 on February 12, 2026. The Annual Report is available on Fagron's in both Dutch (official version, including the ESEF-tagged version) and English. It comprises the annual financial report relating to the consolidated f...

7h / 20m 1 EN
 PRESS RELEASE
Free
FAGR FAGRON SA

Fagron publiceert haar Jaarverslag 2025

Fagron publiceert haar Jaarverslag 2025 Gereglementeerde informatieNazareth (België)/Rotterdam (Nederland), 6 maart 2026 – 7:00 CET Fagron publiceert haar Jaarverslag 2025 Fagron, de toonaangevende wereldwijde speler in farmaceutische bereidingen, publiceert vandaag haar Jaarverslag 2025, volgend op de eerdere bekendmaking van Fagron's jaarlijkse financiële resultaten over het boekjaar 2025 op 12 februari 2026.  Het Jaarverslag is beschikbaar op de van Fagron in zowel het Nederlands (officiële versie, inclusief ESEF-getagde versie) als in het Engels. Het Jaarverslag omvat het financieel...

7h / 20m 1 EN
 PRESS RELEASE
Free
FAGR FAGRON SA

Fagron completes acquisition of Vepakum

Fagron completes acquisition of Vepakum Regulated information – inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 3 March 2026 – 7:00AM Fagron completes acquisition of Vepakum Fagron, the leading global player in pharmaceutical compounding, announces the successful completion of its acquisition of Vepakum in Latin America. The transaction, announced in December 2025, was finalized following regulatory clearance from CADE in early February 2026. Vepakum operates two facilities in São Paulo, Brazil, and specializes in high-quality pharmaceutical packaging solutions. The ac...

March 3, 2026 1 EN
 PRESS RELEASE
Free
FAGR FAGRON SA

Fagron voltooit overname van Vepakum

Fagron voltooit overname van Vepakum Gereglementeerde informatie - voorwetenschapNazareth (België)/Rotterdam (Nederland), 3 maart 2026 – 7:00 Fagron voltooit overname van Vepakum Fagron, de toonaangevende wereldwijde speler in farmaceutische bereidingen, maakt bekend dat de overname van Vepakum in Latijns-Amerika succesvol is afgerond. De transactie, die in december 2025 werd aangekondigd, kon worden voltooid nadat CADE, de Braziliaanse mededingingsautoriteit, in februari 2026 goedkeuring verleende. Vepakum beschikt over twee productiefaciliteiten in São Paulo, Brazilië, en is gespecial...

March 3, 2026 1 EN
 PRESS RELEASE
Free
FAGR FAGRON SA

Disclosure of a transparency notification from AOC Pharma S.à r.l.

Disclosure of a transparency notification from AOC Pharma S.à r.l. Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 27 02 2026 – 6PM CET Disclosure of a transparency notification from AOC Pharma S.à r.l. Pursuant to the Belgian Act of 2 May 2007 on the disclosure of major shareholdings in listed companies, Fagron received a transparency notification from AOC Pharma S.à r.l., dated 24 February 2026. Notification from AOC Pharma S.à r.l. On 24 February 2026, Fagron received a transparency notification from AOC Pharma S.à r.l., informing the Company that its sharehold...

February 27, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch